Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > BUSINESS
BUSINESS
- Novartis Takes Over Radioligand Therapy Lutathera from Fujifilm in Japan
April 3, 2023
- Shionogi’s Xocova Now Available through Normal Commercial Channel
April 3, 2023
- Entyvio Hits Primary Goal in Pouchitis Study: Takeda
April 3, 2023
- Ultragenyx Plans Japan Submission of Evinacumab in May: CEO
March 31, 2023
- Takeda’s Iwasaki to Retire as Representative Director
March 31, 2023
- Pfizer Japan Files 20-Valent Pneumococcal Vaccine for Pediatric Use
March 31, 2023
- Sanofi Launches PD-1 Inhibitor Libtayo in Japan
March 31, 2023
- JCR, Alexion Pair Up for Neurodegenerative Disease
March 31, 2023
- Twymeeg Tops GP Promotion Ranking 2 Months Running, Belsomra Most Detailed among HPs in February
March 31, 2023
- Merck Poised to Work Together with Japan towards 90% HPV Vaccine Rate: Exec
March 31, 2023
- Astellas, Roche to Develop Combo Medical Device Solution for Diabetes
March 30, 2023
- Boehringer’s Japan Human Pharma Sales Up 5.6% in 2022
March 30, 2023
- Simulation Driven Decision-Making Support Necessary for R&D Strategy: Astellas Exec
March 29, 2023
- Pfizer Files Tick-Borne Encephalitis Vaccine in Japan
March 29, 2023
- Mochida, Human Life CORD Tie Up on Cell-Based Product in Japan
March 29, 2023
- Estimated 37,746 Patients Given Xocova as of March 19: Shionogi
March 29, 2023
- Japan Industry Frets Fate of Astellas Worker Held in China for Espionage Allegation
March 28, 2023
- Janssen, Labor Union at Odds over Proposed Job Transfers: 2nd Bargaining Session
March 28, 2023
- Santen Files Epinastine Ophthalmic Cream for Allergic Conjunctivitis
March 28, 2023
- Teva Takeda to Copromote Allermist AG with Ceolia
March 28, 2023
ページ
Japan is opening a new chapter in sleep medicine. The recent decision to allow medical institutions to advertise “sleep disorders”…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…